Premium
CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells
Author(s) -
Hasegawa Masaki,
Hagiwara Sumitaka,
Sato Tomoko,
Jijiwa Mayumi,
Murakumo Yoshiki,
Maeda Masahiro,
Moritani Suzuko,
Ichihara Shu,
Takahashi Masahide
Publication year - 2007
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2007.02097.x
Subject(s) - myoepithelial cell , ductal cells , prostate , pathology , basal (medicine) , lacrimal gland , mammary gland , biology , prostate cancer , salivary gland , medicine , immunohistochemistry , breast cancer , cancer , endocrinology , insulin
The CD109 gene encodes a glycosylphosphatidylinositol (GPI)‐anchored cell surface protein. Herein it is shown that CD109 is highly expressed in myoepithelial cells of mammary, salivary, and lacrimal glands; and in prostate basal cells. The anti‐CD109 antibody generated by the authors was available for formalin‐fixed paraffin section, and it strongly stained myoepithelial cells and basal cells but not ductal, acinar, and secretory cells in these glands. CD109 expression was negative in examined breast ductal carcinomas and prostate adenocarcinomas. These findings indicate that CD109 is a useful marker for the diagnosis of invasive breast and prostate carcinomas.